Skip to main content
SpringerLink
Log in

Advances in Vaccine Technology

  • Chapter
  • First Online:
Recurrent Respiratory Papillomatosis

  • 431 Accesses

Abstract

Human papillomaviruses (HPVs) are the causative agent for recurrent respiratory papillomatosis, cancer of the cervix, and squamous cell carcinoma of the head and neck. Vaccines are available to prevent infection with several of the HPV types that are responsible for causing these serious diseases. This chapter discusses the development, successes, and limitations of these prophylactic L1-based vaccines. Potential for L2-based vaccines to provide broad coverage to prevent infection with many HPV types is also discussed. Finally, research into treatment of established HPV infection and resultant disease using therapeutic vaccines is outlined.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • (CDC) CfDCaP. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep. 2013;62(29):591–5.

    Google Scholar 

  • Angioli R, Lopez S, Aloisi A, Terranova C, DeCicco C, et al. Ten years of HPV vaccines: state of art and controversies. Crit Reviews Oncol Hematol. 2016;102:65–72.

    Article  Google Scholar 

  • Bayas JM, Costas L, Munoz A. Gynecol Oncol. Cervical cancer vaccination indications, efficacy, and side effects. 2008;110(3 Suppl 2):S11–4.

    CAS  Google Scholar 

  • Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27:5450–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brotherton JML, Ogilvie GS. Current status of human papillomavirus vaccination. Curr Opin Oncol. 2015;27:399–404.

    Article  CAS  PubMed  Google Scholar 

  • Castellsague X, Bosch FX, Munoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105–12.

    Article  PubMed  Google Scholar 

  • Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2016;144:449–68.

    Article  CAS  PubMed  Google Scholar 

  • Centers for Disease Control and Prevention. Human papillomavirus-associated cancers—United States, 2004–2008. Morbidity Mortality Weekly Rep. 2012;61(15):258–61.

    Google Scholar 

  • Chatterjee A. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines. 2014;13(11):1279–90.

    Article  CAS  PubMed  Google Scholar 

  • Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40(2):108–15.

    Article  PubMed  Google Scholar 

  • Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe. 2010;8:260–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis; a review. Laryngoscope. 2008;118:1236–47.

    Article  PubMed  Google Scholar 

  • Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802.

    Article  CAS  PubMed  Google Scholar 

  • Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR. Prevalence of HPV infection among men: a systematic review of the literature. J Infect Dis. 2006;194:1044–57.

    Article  PubMed  Google Scholar 

  • Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect. 2009;85:499–502.

    Article  CAS  PubMed  Google Scholar 

  • Farrow AL, Rachakonda G, Gu L, Krendelchtchikova V, Nde PN, Pratap S, et al. Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2014;8(8):e3089.

    Article  PubMed  PubMed Central  Google Scholar 

  • Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657–65.

    Article  PubMed  Google Scholar 

  • Fraillery D, Baud D, Pang SY. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol. 2007;14:1285–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garland SM. The Australian experience with the human papillomavirus vaccine. Clinical Therapeut. 2014;36:17–23.

    Article  Google Scholar 

  • Gérard CM, Baudson N, Kraemer K, Bruck C, Garçon N, Paterson Y, Pan ZK, Pardoll D. Therapeutic potential of protein and adjuvant vaccinations on tumour growth. Vaccine. 2001;19(17–19):2583–9.

    Article  PubMed  Google Scholar 

  • Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113(10 Suppl):3036–46.

    Article  PubMed  Google Scholar 

  • Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomark Prev. 2008a Aug;17(8):2036–43.

    Article  CAS  Google Scholar 

  • Giuliano AR, Lu B, Nielson CM, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis. 2008b;198:827–35.

    Article  PubMed  Google Scholar 

  • Giuliano AR, Palefksy JM, Goldstone S, et al. Efficacy of Quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guo T, Eisele DW, Fahkry C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer. 2016;122(15):2313–23.

    Article  PubMed  PubMed Central  Google Scholar 

  • Handler MZ, Handler NS, Majewski S, Schwartz RA. Human papillomavirus vaccine tirals and tribulations: clinical perspectives. J Am Acad Dermatol. 2015;73:743–56.

    Article  PubMed  Google Scholar 

  • Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and nutrition examination survey, 2003–2006. J Infect Dis. 2011;204(4):566–73.

    Article  PubMed  Google Scholar 

  • Harper DM, Vierthaler SL, Santee JA. Review of Gardasil. J Vaccines Vaccin. 2010;1(107):1000107.

    PubMed  PubMed Central  Google Scholar 

  • Harro CD, Pang YY, Roden RB, Hildesheim A. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284–92.

    Article  CAS  PubMed  Google Scholar 

  • Hermann JS, Weckx LY, Nurnberger JM, Dos Santos Junior GF, et al. Effectiveness of the human papillomavirus (types 6,11,16,18) vaccine in the treatment of children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2016;83:94–8.

    Article  PubMed  Google Scholar 

  • Herrero R, Gonzalez P, Markowitz LE. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015;16:e206–16.

    Article  CAS  PubMed  Google Scholar 

  • Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, et al. Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743–53.

    Article  CAS  PubMed  Google Scholar 

  • Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst. 2009;101(11):782–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jagu S, Kwak K, Karanam B, Huh WK, Damotharan V, Chivukula SV, et al. Optimization of multimeric human papillomavirus L2 vaccines. PLoS One. 2013;8(1):e55538.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jeyakumar A, Mitchell M. HPV vaccination and recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 2011;144:133.

    Article  PubMed  Google Scholar 

  • Karanam B, Jagu S, Huh WK, Roden RB. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009a;87(4):287–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Karanam B, Jagu S, Huh WK, Roden RBS. Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. Immunol Cell Biol. 2009b;87:287–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kenter GG, Welters MJP, Valentijn ARPM, Lowik MJG, et al. Vaccination against HPV-16 Oncoproteins for vulvar intraepithelial Neoplasia. N Engl J Med. 2009;361:1838–47.

    Article  CAS  PubMed  Google Scholar 

  • Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645–51.

    Article  CAS  PubMed  Google Scholar 

  • Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prevent Res (Philadelphia). 2012;5(1):18–23.

    Article  Google Scholar 

  • Makiyama K, Hirai R, Matsuzaki H. Gardasil vaccination for recurrent laryngeal papillomatosis in adult men; changes in HPV antibody titer. J Voice. 2016;Pii:S0892–1997. doi:10.1016/j.jvoice.2016.01.008.

    Google Scholar 

  • Markowitz LE, Dunne EF, Saraiya M, Lawson HW, et al. Quadrivalent human papilloma vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007;23(56(RR-2):1–24.

    Google Scholar 

  • Markowitz LE, Tsu V, Deeks SL, Cubie H, et al. Human papillomavirus vaccine introduction-the first five years. Vaccine. 2012;30S:F139–48.

    Article  Google Scholar 

  • Marlow LA, Forster AS, Wardle J, Waller J. Mothers' and adolescents' beliefs about risk compensation following HPV vaccination. J Adolesc Health. 2009;44(5):446–51.

    Article  PubMed  Google Scholar 

  • Nygård M, Krüger Kjaer S, Dillner J, et al. Long-term effectiveness and immunogenicity of Gardasil™ in the Nordic countries. In: Poster presented at Eurogin 2013: HPV at a Crossroads – 30 Years of Research and Practice; 3–6 Nov 2013. Florence, Italy.

    Google Scholar 

  • Palefsky JM, Giuliano AR, Goldstone S. HPV vaccine against anal HPV infection and anal intraepithelial Neoplasia. N Engl J Med. 2011;365(17):1576–85.

    Article  CAS  PubMed  Google Scholar 

  • Pastrana DV, Gambhira R, Buck CB, Pang YY, Thompson CD, Culp TD, et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology. 2005;337(2):365–72.

    Article  CAS  PubMed  Google Scholar 

  • Peng S, Tomson TT, Trimble C, He L, Hung CF, Wu TC. A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther. 2006;13:257–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Peng S, Best SR, Hung CF, et al. Characterization of human papillomavirus type 11-specific immune responses in a preclinical model. Laryngoscope. 2010;120(3):504–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Peng S, Song L, Knoff J, Wang JW, et al. Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci. 2014;4(1):11.

    Article  PubMed  PubMed Central  Google Scholar 

  • Peng S, Mattox A, Best SR, et al. Identification of the murine H-2D(B) and human HLA-A*0201 MHC class i-restricted HPV6 E7-specific cytotoxic t lymphocyte epitopes. Cancer Immunol Immunother. 2016;65(3):261–71. Epub 2016 Jan 13

    Article  CAS  PubMed  Google Scholar 

  • Ports KA, Barnack-Tavlaris JL, Mosavel M, et al. Young Women’s sexual and reproductive health post HPV vaccination Womens Reprod health. Womens Reprod Health. 2014;1(1):43–55.

    Article  PubMed Central  Google Scholar 

  • Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007;13(7):857–61.

    Article  CAS  PubMed  Google Scholar 

  • Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 2000;270(2):254–7.

    Article  CAS  PubMed  Google Scholar 

  • Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schellenbacher C, Kwak K, Fink D, Shafti-Keramat S, Huber B, Jindra C, et al. Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol. 2013;133(12):2706–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol. 1996;7:373–82.

    Article  CAS  PubMed  Google Scholar 

  • Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26(Suppl 10):K53–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shah KV. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent vaccine to prevent juvenile-onset laryngeal papilloma. J Infect Dis. 2014;209:1307–9.

    Article  CAS  PubMed  Google Scholar 

  • Sharma A, Krause A, Xu Y, Sung B, Wu W, Worgall S. Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas Aeruginosa. PLoS One. 2013;8(2):e56996.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • van der Sluis TC, Sluijter M, van Duikeren S, West BL, Melief CJ, Arens R, et al. Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression. Cancer Immunol Res. 2015;3(9):1042–51.

    Article  PubMed  Google Scholar 

  • State Vaccination Requirements. 29 Jan 2016. Retrieved July 19, 2016, from http://www.cdc.gov/vaccines/imz-managers/laws/state-reqs.html.

  • Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995;92(25):11553–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • TjonPianGi REA, San Giorgi MRM, Pawlita M, Michel A, et al. Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis. Arch Otorhinolaryngol. 2016;273:3231–6. doi:10.1007/s00405-016-4085-3.

    Article  Google Scholar 

  • Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus. PLoS One. 2012;7(11):e49751.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang JW, Roden RB. Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev Vaccines. 2013;12(2):129–41.

    Article  CAS  PubMed  Google Scholar 

  • Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach. Virol J. 2015;12:140.

    Article  PubMed  PubMed Central  Google Scholar 

  • Yoon SW, Lee TY, Kim SJ, Lee IH, Sung MH, Park JS, et al. Oral administration of HPV-16 L2 displayed on lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice. Vaccine. 2012;30(22):3286–94.

    Article  CAS  PubMed  Google Scholar 

  • Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine (Gardasil) as adjuvant therapy for treatment of recurrent respiratory papilloma. J Voice 2015; 229:223–229.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otolaryngology—Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, 21287-0910, USA

    Julie Ahn, Simon R. A. Best & David E. Tunkel

Authors
  1. Julie Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Simon R. A. Best
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David E. Tunkel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David E. Tunkel .

Editor information

Editors and Affiliations

  1. Department of Otolaryngology - Head and Neck Surgery, University of Toronto, Toronto, Ontario, Canada

    Paolo Campisi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Ahn, J., Best, S.R.A., Tunkel, D.E. (2018). Advances in Vaccine Technology. In: Campisi, P. (eds) Recurrent Respiratory Papillomatosis. Springer, Cham. https://doi.org/10.1007/978-3-319-63823-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-63823-2_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-63822-5

  • Online ISBN: 978-3-319-63823-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation